Sugi Predict

Sugi Predict / Compounds / SCHEMBL6447258

SCHEMBL6447258

SCHEMBL6447258

CC(C)(C)OC(=O)NNCc1ccc(-c2ccccc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 1/20 0.52
▸ CA12 O43570 1/20 0.51
▸ CA1 P00915 1/20 0.51
▸ CA7 P43166 1/20 0.51
▸ CA14 Q9ULX7 1/20 0.51
▸ CTSK P43235 2/20 0.51
▸ CTSS P25774 1/20 0.51
▸ GAA P10253 2/20 0.48
▸ PPARA Q07869 3/20 0.47
▸ ATM Q13315 1/20 0.47
▸ PPARG P37231 2/20 0.45
▸ BCL2 P10415 1/20 0.45
▸ CYP17A1 P05093 1/20 0.45
▸ NPC1 O15118 2/20 0.45
▸ RAB9A P51151 2/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ ALDH1A1 P00352 1/20 0.44
▸ LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4632779 0.91 CA12 (0.60) CA12CA1CA7CA14CTSK
SCHEMBL9971046 0.86 GAA (0.50) HDAC1CTSKCTSSGAA
SCHEMBL6234 0.86 NAMPT (0.52) CYP17A1RAB9ALMNA
SCHEMBL1691047 0.85 HDAC1 (0.67) HDAC1CA12CA1CA7CA14
SCHEMBL6445761 0.84 ESRRG (0.55) CA12CA1CA7CA14CTSK
SCHEMBL6243210 0.83 HDAC1 (0.54) HDAC1CA12CA1CA7CA14
SCHEMBL9971059 0.83 GAA (0.51) CA12CA1CA7CA14CTSK
SCHEMBL6236607 0.83 GAA (0.51) CA12CA1CA7CA14GAA
SCHEMBL6692 0.83 TRPV1 (0.44) HDAC1CA12CA1CA7CA14
SCHEMBL30637051 0.83 TRPV1 (0.44) HDAC1CA12CA1CA7CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230285340-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP LLC (US) 2023-09-14 — — US disclosed
US-11547687-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2023-01-10 — — US disclosed
US-20210059966-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2021-03-04 — — US disclosed
US-10744104-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2020-08-18 — — US disclosed
US-20190262297-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2019-08-29 — — US disclosed
US-20180051023-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2018-02-22 — — US disclosed
US-9873696-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2018-01-23 — — US disclosed
US-9873696-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2018-01-23 — — US disclosed
US-9725448-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-08-08 — — US disclosed
US-20170217959-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-08-03 — — US disclosed
EP-1392315-A1 METHODS OF TREATING ALZHEIMER'S DISEASE Elan Pharmaceuticals, Inc. (US) 2004-03-03 — — EP disclosed
WO-2002100410-A1 METHODS OF TREATING ALZHEIMER'S DISEASE ELAN PHARMACEUTICALS, INC. (US) 2002-12-19 — — WO disclosed
EP-0876336-B1 AZAHEXANE DERIVATIVES AS SUBSTRATE ISOSTERS OF RETROVIRAL ASPARATE PROTEASES NOVARTIS AG (CH) 2002-06-05 — — EP disclosed
US-5990135-A FOR TREATING A RETROVIRAL INFECTION SUCH AS HIV INFECTION; FOR EXAMPLE 5S-N-((2-PYRIDINYL)METHOXYCARBONYL)VALINYLAMINO-2-((N-3 -PYRIDINYL)METHOXYCARBONYL)AMINO-4S-HYDROXY-1,6-DIPHENYL-2-AZAHEXANE AND OTHER COMPOUNDS OF GIVEN FORMULA ABBOTT LABORATORIES (US) 1999-11-23 — — US disclosed
US-5631376-A PEPTIDE DERIVATIVES FOR TREATMENT OF AIDS ABBOTT LABORATORIES (US) 1997-05-20 — — US disclosed
US-5621109-A OXAZOLE/THIAZOLE DERIVATIVES OF HYDROXYMETHYL HYDRAZONES; SIDE EFFECT REDUCTION ABBOTT LABORATORIES (US) 1997-04-15 — — US disclosed
EP-0683772-A1 RETROVIRAL PROTEASE INHIBITING COMPOUNDS ABBOTT LABORATORIES (US) 1995-11-29 — — EP disclosed
US-5461067-A For HIV infections ABBOTT LABORATORIES (US) 1995-10-24 — — US disclosed
EP-0683772-A4 RETROVIRAL PROTEASE INHIBITING COMPOUNDS. ABBOTT LAB (US) 1995-09-27 — — EP disclosed
WO-1994019332-A1 RETROVIRAL PROTEASE INHIBITING COMPOUNDS ABBOTT LABORATORIES (US) 1994-09-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230285340-A1 NEPRILYSIN INHIBITORS MME, REN, ACE HDAC1 788/4885CA12 3259/4885CA1 2927/4885
US-11547687-B2 Neprilysin inhibitors MME, REN, ACE HDAC1 788/4885CA12 3259/4885CA1 2927/4885
US-10744104-B2 Neprilysin inhibitors MME, REN, ACE HDAC1 788/4885CA12 3259/4885CA1 2927/4885
US-20170217959-A1 NEPRILYSIN INHIBITORS MME, REN, ACE HDAC1 1103/4885CA12 3736/4885CA1 2916/4885
US-20210059966-A1 NEPRILYSIN INHIBITORS MME, REN, ACE HDAC1 788/4885CA12 3259/4885CA1 2927/4885
US-20190262297-A1 NEPRILYSIN INHIBITORS MME, REN, ACE HDAC1 788/4885CA12 3259/4885CA1 2927/4885
US-20180051023-A1 NEPRILYSIN INHIBITORS MME, REN, EDNRB HDAC1 896/4885CA12 3576/4885CA1 2840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.